Question explored with the scientific record
how does the shingles vaccine work and is it safe and effective?
The shingles vaccine works by training your immune system to recognize a single viral protein, but the evidence for its safety is thinner than the efficacy numbers suggest.
The recombinant zoster vaccine (Shingrix) uses a piece of the virus called glycoprotein E, mixed with a strong adjuvant (AS01B) that deliberately triggers a powerful inflammatory response [2]. This is not a live virus. The goal is to produce antibodies and T-cells that stop the virus from reactivating. In the manufacturer-funded ZOE trials, two doses cut shingles cases by about 97% in people aged 50 and older, and by about 90% in those 70 and older [3, 4]. That protection held at roughly 84% through year eight [3]. For people with weakened immune systems, the effectiveness was lower: about 68% in stem-cell transplant recipients [4].
The safety picture is more complicated. In the trials, about 8 in 10 people had injection-site reactions, and about 6 in 10 had systemic reactions like fever or muscle pain [6]. Most lasted a few days [5]. The trials were too small to catch rare but serious harms. After millions of doses were given, a signal for Guillain-Barré syndrome emerged: about 3 extra cases per million doses within 42 days of vaccination [3]. That is a small absolute risk, but it is real. The long-term safety data beyond nine years is limited, and the extension studies were funded by the manufacturer [1].
| Group | Shingles cases per 1,000 person-years (unvaccinated) | Shingles cases per 1,000 person-years (vaccinated) | Approximate reduction |
|---|---|---|---|
| Adults 50+ (ZOE-50 trial) | 9.1 | 0.3 | 97% |
| Adults 70+ (ZOE-70 trial) | not shown directly | not shown directly | 90% |
| Medicare beneficiaries 65+ (real-world) | not shown directly | not shown directly | 70% |
| Stem-cell transplant recipients | not shown directly | not shown directly | 68% |
The real-world effectiveness is lower than the trial numbers: about 70% in a large Medicare study, not 97% [3]. That matters because the trials excluded many people with complex health conditions. The vaccine is expensive, requires two doses, and causes enough side effects that some people skip the second dose.
My call: for an older adult with a healthy immune system who accepts the trade-off of short-term reactions for a high chance of avoiding a painful illness, the vaccine is worth considering. The confidence is moderate: the short-term efficacy is well-proven, but the long-term safety data is incomplete and the real-world effectiveness is lower than advertised.
Sources used 6
-
Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial
Nine-year follow-up of adults aged ≥60 who received the herpes zoster subunit vaccine (HZ/su) shows durable gE-specific cellular and humoral immunity with a favorable safety profile, extending immune persistence beyond prior 6-year data.
DOI: 10.1093/ofid/ofx163.1040 -
Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine
A comprehensive review detailing how the Shingrix recombinant gE herpes zoster vaccine, with the AS01_B adjuvant, elicits robust humoral and polyfunctional CD4+ T cell responses, achieving high and durable protection against herpes zoster across older adults and various immunoco…
DOI: 10.1016/j.coi.2019.02.009 -
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
This narrative review finds real-world vaccine effectiveness of about 46% for live zoster vaccine and about 85% for recombinant zoster vaccine, with mostly local reactions and a small Guillain-Barré syndrome signal to monitor.
DOI: 10.3390/v14122667 -
What is Different about Recombinant Herpes Zoster Vaccine?
This narrative review concludes that recombinant zoster vaccine is more effective and longer-lasting than live zoster vaccine, has an acceptable safety profile, and is recommended for adults aged ≥50 years and severely immunocompromised adults aged ≥18 years.
DOI: 10.3904/kjm.2024.99.4.180 -
Healthy ageing: Herpes zoster infection and the role of zoster vaccination
This narrative review concludes that adjuvanted recombinant zoster vaccine prevents herpes zoster and postherpetic neuralgia, has a reassuring safety profile, and is a key action for healthy ageing.
DOI: 10.1038/s41541-023-00757-0 -
Herpes zoster subunit vaccine for the prevention of herpes zoster
This study reviews the efficacy and safety of the herpes zoster subunit vaccine (HZ/su vaccine) in preventing herpes zoster and postherpetic neuralgia in adults aged 50 and older, highlighting its superior efficacy compared to the live attenuated vaccine.
DOI: 10.2146/ajhp170399